EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Effect of Levetiracetam on Improving Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients: A Pilot Double-Blind Randomized Placebo-Controlled Clinical Trial

Maryam Sharif, Hooshyar Honarmand, Fahime Vahabizad, Mohammad Ali Sahraian, Mojtaba Mojtahedzadeh, Samira Navardi, Nasim Rezaeimanesh, Efat Davoudi, Roghayeh Saeedi, Kourosh Sadeghi, Abdorreza Naser Moghadasi

Journal of Reports in Pharmaceutical Sciences · 2024

DOI: 10.5812/jrps-153995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Reports in Pharmaceutical Sciences, 2024. Verfasst von Maryam Sharif und 10 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cognitive impairment has been identified in all stages and affects all subtypes of multiple sclerosis (MS) (40 - 65% of people with clinically definite MS). A defined therapeutic strategy has not yet been determined.

Objectives

This study aimed to assess the efficacy of levetiracetam (LEV) to improve cognitive impairments in patients with relapsing-remitting MS (RRMS).

Methods

A Pilot randomized; double-blinded, placebo-controlled clinical trial was conducted. The patients with a definite diagnosis of RRMS treated with first-line drugs. They were assigned into two groups; LEV and the placebo for four months. The primary outcome was the changes in cognitive domains based on the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) compared to baseline. The MACFIMS was accomplished by seven tests: California verbal learning test-II (CVLT-II), paced auditory serial addition test (PASAT), symbol digit modalities testing (SDMT), brief visuospatial memory test-revised (BVMT-R), delis-Kaplan executive function system (D-KEFS), controlled oral word association test (COWAT), and judgment of line orientation (JLO).

Results

A total of 32 patients entered the study and 28 patients completed the trial. The change in JLO score in the LEV group was significantly greater than in the placebo group (P-value = 0.03). After intervention in the LEV group, the SDMT and JLO scores were significantly higher than the baseline scores.

Conclusions

This is the study to evaluate the effects of LEV on cognitive disorders in patients with MS. Levetiracetam was significantly effective in improving the JLO and SDMT scores in patients with RRMS compared to the placebo group.

Zitieren

APA

Sharif, M., Honarmand, H., Vahabizad, F., Sahraian, M. A., Mojtahedzadeh, M., Navardi, S., Rezaeimanesh, N., Davoudi, E., Saeedi, R., Sadeghi, K., & Moghadasi, A. N. (2024). The Effect of Levetiracetam on Improving Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients: A Pilot Double-Blind Randomized Placebo-Controlled Clinical Trial. Journal of Reports in Pharmaceutical Sciences. https://doi.org/10.5812/jrps-153995

Vancouver

Sharif M, Honarmand H, Vahabizad F, Sahraian MA, Mojtahedzadeh M, Navardi S, et al. The Effect of Levetiracetam on Improving Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients: A Pilot Double-Blind Randomized Placebo-Controlled Clinical Trial. Journal of Reports in Pharmaceutical Sciences. 2024. doi:10.5812/jrps-153995

BibTeX
@article{Sharif2024,
  author = {Sharif, Maryam and Honarmand, Hooshyar and Vahabizad, Fahime and Sahraian, Mohammad Ali and Mojtahedzadeh, Mojtaba and Navardi, Samira and Rezaeimanesh, Nasim and Davoudi, Efat and Saeedi, Roghayeh and Sadeghi, Kourosh and Moghadasi, Abdorreza Naser},
  title = {The Effect of Levetiracetam on Improving Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients: A Pilot Double-Blind Randomized Placebo-Controlled Clinical Trial},
  journal = {Journal of Reports in Pharmaceutical Sciences},
  year = {2024},
  doi = {10.5812/jrps-153995}
}
Kostenlos starten →